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EXPRESSED WILLINGNESS TO PARTICIPATE IN FIVE-YEAR ANAL 
CANCER PREVENTION STUDY AFTER PARTICIPATION IN 
PREVIOUS ANAL CANCER PREVENTION STUDY 
 
MADELINE RACHAEL MACDONALD 
ABSTRACT 
  
Introduction: Anal cancer is increasing in the population, especially in HIV positive 
individuals. The group that currently has the highest incidence of anal cancer is HIV 
positive men who have sex with men. There are a number of treatment methods available 
to prevent pre-cancerous lesions called high grade squamous intraepithelial lesions 
(HSIL) from developing into cancer, however, these treatments are not currently routine. 
Randomized control trials are currently being conducted to assess the efficacy of these 
treatments in preventing anal cancer in high-risk populations. It is important to 
understand the motivations of individuals who are seeking to participate in anal cancer 
prevention studies. It is also important to learn about the experiences of participants who 
have enrolled in anal cancer prevention studies, and have in some situations undergone 
invasive procedures to treat their HSIL.  
Methods: Participants in the AMC 076 study, an anal cancer prevention randomized 
control trial were recruited for the IMPACT 076 study. Two phone interviews were 
conducted and audio recordings were saved. Transcripts of the first set of interviews for 
21 participants were analyzed and coded to gather qualitative data on the willingness of 
participants in the AMC 076 study to participate in a five-year anal cancer prevention 
  v 
study based on their experiences with pain and/or side effects in AMC 076. The research 
question about participation in the five-year study was hypothetical and not for the 
purpose of recruitment for the five-year study.  
Results/Discussion: We categorized participants into one of four groups: treatment 
group/treatment naïve, treatment group/treatment experienced, observation group/ 
treatment naive, and observation group/treatment experienced. When considering all 
participants who have received treatment at some point (either in the study or before the 
study), nine out of the thirteen would be willing to participate in the five-year study, three 
would not, and one was undecided.  
We concluded that previous pain or side effects did not appear to deter 
participants from participating in a five-year study. Based on the results of this study, the 
most common motivator for participation appeared to be altruism. The most common 
deterrent for participating in the five-year study was participants feeling that five years is 
too long to have their HSIL left untreated if they were to be randomized to the 
observation arm of the five-year study. Overall, participants were willing to deal with the 
pain and/or side effects of the exams and/or treatments in exchange for the feeling 
confident that their HSIL was removed or monitored and their risk of developing anal 
cancer is greatly reduced.  
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INTRODUCTION 
As of 2010, anal cancer affects approximately 1.5/100,000 men and 1.9/100,000 
women in the United States, which is relatively low compared to other types of cancers 
(Palefsky, 2015). Individuals infected with the Human Immunodeficiency Virus (HIV) 
and other immunosuppressed individuals have a much higher incidence of anal cancer 
(Battaglia et al., 2015). Other groups of people that have a higher incidence of anal 
cancer include men who have sex with men (MSM), men and women who are 
immunosuppressed due to organ transplant, men and women with a history of genital 
warts, and women with a history of Human papillomavirus (HPV) related disease 
including cancer (Berry et al., 2013). The group that has the highest risk for anal cancer 
includes MSM who are infected with HIV (Ong et al., 2015). The increase in the 
incidence of anal cancer in men who are infected with HIV has increased from 1.1% to 
28.4% from 1980 to 2005 and from 0% to 1.2% in HIV infected females (Shiels et al., 
2012). This increase has been most prominent since the development of Highly Active 
Antiretroviral Therapy (HAART). This is likely due to a number of factors including HIV 
positive individuals living longer due to the medications, with the incidence of anal 
cancer increasing with age in both men and women (Silverberg et al., 2012). The risk of 
anal cancer is 80 times higher in HIV infected men who have sex with men and 32 times 
higher in other men (Berry et al., 2013). HIV positive women are 24 times more likely to 
have anal cancer than HIV negative women (Shiels et al., 2012). As evidenced by the 
above statistics, the incidence of anal cancer is dramatically disproportionate amongst 
HIV positive individuals and HIV negative individuals (Ka‘opua et al., 2016). Anal 
 2 
cancer is the most prevalent non-AIDS defining cancer in HIV positive individuals (Ong, 
2015).  
Prevention of Anal Cancer 
Methods to prevent anal cancer, specifically in high-risk groups such as HIV 
positive individuals have been and are currently being researched. Early detection of 
localized anal cancer provides approximately 78% survival over a 5-year period (Ong et 
al., 2015). One preventative measure is vaccination against the Human papillomavirus 
(HPV). HPV infection is the most ubiquitous sexually transmitted infection (STI) and 
often goes unnoticed by individuals who are infected with the virus (CDC, 2016). The 
immune system can often prevent HPV related symptoms and disease from developing in 
healthy individuals (Ka‘opua et al., 2016). Individuals who are immunocompromised, 
such as those who are infected with HIV have a higher risk of developing HPV related 
diseases than the general population (Mortensen and Larsen, 2010). HPV related diseases 
include warts, low-grade squamous intraepithelial lesions (LSIL), high grade squamous 
intraepithelial lesions (HSIL), and cancers of the oral, anal, cervical and genital mucosae 
(Mortensen and Larsen, 2010). Risk factors for HPV related diseases include unprotected 
vaginal and/or anal intercourse, sex with multiple partners, and immunosuppression due 
to HIV infection or other causes (Joseph et al., 2008). If people are vaccinated before 
they are exposed or infected with HPV 16 and/or HPV 18 (the high risk strains of HPV), 
HPV related disease may be prevented (Newman et al., 2008). Approximately 90% 
percent of cases of anal cancer have been associated with HPV infection (Hernandez et 
al., 2014). Receptive anal sex, low nadir CD4+ count, having sex with multiple partners, 
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and recent sexual intercourse are the main risk factors for developing an anal cancer 
prone HPV infection (Hernandez et al., 2014). While the HPV vaccine is recommended 
for 9-26 year old males and females, the uptake of the vaccine is much lower in males 
(Castle, 2009). In addition to preventing cervical cancer, the vaccine has been noted to 
decrease the incidence of genital warts (Machalek et al., 2012). A recent study on the 
prevalence of HPV infection in women in the United States evidenced that there was a 
64% decrease in HPV infection in 14 to 19 year old women and a 34% decrease in 20 to 
24 year old women since the introduction of the HPV vaccine (Markowitz et al., 2016). It 
is possible that herd effects could be contributing to the decrease in HPV infection 
(Markowitz et al., 2016).  Many HIV positive individuals are too old to qualify for the 
vaccine and they most likely have already been exposed to HPV-16 and 18 through sex 
(Newman et al., 2008). For individuals who have already been exposed to HPV-16 and 
18, secondary prevention is another way to reduce the risk of anal cancer.  
Secondary prevention methods include screening and treating High Grade 
Squamous Intraepithelial Lesions (HSIL), to ultimately prevent HSIL from developing 
into anal neoplasia (Berry et al., 2013). Anal HSIL, also referred to as high-grade anal 
intraepithelial neoplasia (HGAIN), is dysplasia, or damaged areas of anal mucosa that are 
not malignant, but have the potential to develop into cancer (Berry et al., 2013). Both 
HIV negative and HIV positive individuals who are co-infected with HPV-16 or 18 can 
develop HSIL and subsequently anal cancer, however, HIV positive individuals tend to 
have more complications (Maron and Wexner, 2013). HSIL can be larger in size in HIV 
positive people and is more likely to recur after treatment as compared to HIV negative 
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people (Maron and Wexner, 2013). Approximately 1 out of every 600 HIV positive 
MSM who has HSIL will develop anal cancer each year (Machalek et al., 2012). This rate 
is dramatically disproportionate in HIV negative MSM with HSIL, as approximately 1 
out of every 4000 will develop anal cancer each year (Machalek et al., 2012). 
Screening for Anal Cancer 
Screening for anal cancer involves anal cytology, which is similar to the Pap 
screening test for cervical cancer (Battaglia et al., 2015). Cervical cancer is similar to 
anal cancer in a number of ways, with the most relevant similarity being that cervical 
cancer is caused by HPV infection (Joseph et al., 2008). Unlike screening for cervical 
cancer, however, screening for anal cancer is not routine in HIV care and its efficacy in 
preventing anal cancer is currently being researched (Ong et al., 2015). There is not 
enough research data concluding that treatment of HSIL is effective in reducing the 
incidence of anal cancer. Randomized control trials are currently being conducted to 
compare the efficacy of actively monitoring HSIL as compared to treatment of HSIL 
(Palefsky, 2015). If abnormal results from the anal cytology are discovered, high 
resolution anoscopy (HRA) with anal biopsies can be performed to test for HSIL 
(Battaglia et al., 2015). HRA involves inserting an anoscope into the anus and applying 
acetic acid solution and Lugol’s iodine solution to the anal tissue. The acetic acid and 
Lugol’s iodine solution will temporarily stain abnormal areas in the anal mucosa. These 
areas can be visualized through magnification and use of a colposcope (Palefsky, 2015). 
At this time, HRA is not a routine exam in HIV care. One study provided evidence that 
half of clinics that perform HRA require patients to have results of an abnormal anal 
 5 
cytology before the HRA exam can be performed (Patel et al., 2014). Table 1 includes a 
list of populations that should be considered for anal cancer screening (Palefsky, 2015). 
Currently, an annual digital anorectal exam (DARE) is recommended to feel for 
abnormalities that could indicate anal cancer (Palefsky, 2015). During the DARE the 
length and circumference of the anus are palpated to feel for abnormal areas in the anal 
mucosa (Darragh et al., 2011).  
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Table 1. List of Populations that Should Be Considered for Anal Cancer/ High-
Grade Squamous Intraepithelial Lesion Screening This table was obtained from 
Palefsky, (2015). Immunosuppressed individuals over the age of 25 should be screened 
for anal cancer. Additionally, women and men with HPV related disease should be 
screened.  
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Treatment of HSIL 
Available HSIL treatments include Infrared Coagulation (IRC), hyfrecation/ 
electrocautery, laser removal, treatment under anesthesia, cryotherapy, and topical 
prescription drugs (Darragh et al., 2011). One study provided evidence that infrared 
coagulation is the most common treatment for anal HSIL and accounts for 61% of treated 
cases. The topical prescription drug Imiquimod is the second most common treatment 
(Patel et al., 2014).  
Infrared Coagulation is an ablative treatment that can be used to remove HSIL. It 
is also used in the treatment of anal condyloma (warts) and hemorrhoids (Weis, 2013). 
This procedure can be performed on an outpatient basis and involves a device that 
delivers pulses of infrared and visible light to the HSIL (Darragh et al., 2011). The 
treatment results in necrosis of the targeted tissue and will thereby leave some 
inflammation. Infrared Coagulation is a safe procedure and is typically well tolerated by 
patients (Patel et al., 2014). Local anesthetic is injected before the procedure. Side effects 
include bleeding for up to two weeks after the procedure, local pain, and discomfort 
associated with bowel movements. The risk of infection is minimal (Darragh et al., 
2011).  
Hyfrecation/electrocautery is an ablative treatment that has similar outcomes to 
IRC treatment. One difference is that the heat tip of the electroacauterizer is smaller and 
can more precisely target lesions than the IRC probe tip (Weis, 2013). One disadvantage, 
however, is that the procedure generates smoke that must be removed by a smoke 
evacuator to prevent inhalation of smoke and aerosolized tissue matter by both the patient 
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and clinician (Weis, 2013). The treatment of HSIL with both electrocautery and IRC can 
be repeated if lesions reoccur (Richel et al., 2013).  
Carbon dioxide laser treatment can be used to destroy anal HSIL. This treatment 
can be combined with surgical treatment and/or Imiquimod ointment (Weis, 2013).  
If lesions are too large to remove with the methods discussed above, surgical 
treatment under anesthesia (TUA) might be considered. TUA is typically required for 
only a small number of patients who are seeking removal of their HSIL (Pineda et al., 
2008). Post surgical side effects include pain, bleeding, and infection. In order to 
decrease these side effects and to promote healing, patients are advised to keep their stool 
soft with stool softeners and a diet high in fiber and water. Patients are also advised to 
take frequent, warm baths after surgery to relieve pain and promote blood flow to the 
anus, which will aid in the healing process (UCSF Medical Center, 2016).  
Cryotherapy and trichloroacetic acid (TCA) treatment can be used for the removal 
of perianal lesions, but is not typically used for intraepithelial lesions. Cryotherapy 
involves application of liquid nitrogen to the lesion. Additionally, TCA can be applied to 
the treated area after cryotherapy (Darragh et al., 2011). Local side effects are common 
and include blistering and redness of the skin around the treated area. In a retrospective 
study, 32% of patients who were treated with TCA had complete, yet temporary 
clearance of their HSIL lesions. The lesions recurred in approximately 72% of the 
patients in this study (Darragh et al., 2011).  
Another treatment method that can be used when lesions are too extensive for 
electrocautery or IRC is the use of topical agents. Topical 5% flurouracil (5-FU) is 
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applied by the patient to the anus and perianus twice a day for five consecutive days. The 
patient will then wait nine days and repeat the treatment, up to eight times. If the lesion is 
cleared substantially, ablative methods can then be used to remove the rest of the lesion 
(Richel et al., 2013). In a clinical study, 39% of patients’ HSIL lesions were completely 
resolved after treatment with 5-FU ointment (Richel et al., 2013). In anal cancer 
prevention studies that have 5-FU as a treatment option, patients will be asked if they 
plan to become pregnant or father a child during the duration of the study. 5-FU has 
teratogenic properties and it is not safe for a woman who is taking the drug to become 
pregnant or for a man to father a child while on the drug. While it may be difficult to 
predict plans of pregnancy, it is something to consider when enrolling participants 
(Chemocare, 2016).  
Imiquimod cream is another topical agent that can be used to reduce the size of 
HSIL. Imiquimod has proven effective in the treatment of condyloma in HIV positive 
people. One disadvantage is that side effects of this treatment are common and include 
burning, irritation, pain, and itching at the treatment site (Richel et al., 2013). In a 
randomized control trial, Imiquimod completely removed HSIL lesions in approximately 
14% of participants (Richel et al., 2013). Other topical treatments for HSIL include 
Podofilox Gel and Sinecatechins ointment (Darragh et al., 2011).  
Monitoring HSIL 
Another option for prevention of anal cancer that is currently under research is 
active monitoring or observation of HSIL by clinicians. This is a non-treatment approach 
that involves taking biopsies of HSIL every three to six months (Anal Cancer UCSF 
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website, 2016). If lesions become suspicious and start to resemble cancer, clinicians can 
then refer the patient for treatment. Active monitoring can reassure patients that their 
HSIL is being closely watched and if cancer does arise, it will be caught very early, and 
the patient is likely to recover after treatment with radiation and/or chemotherapy (Anal 
Cancer UCSF website, 2016). Progression of HSIL to anal cancer occurs at a rate of 
approximately 15% in HIV positive MSM over a period of two to five years (Richel et 
al., 2013). It is not yet known if treatment of HSIL will lead to reduced rates of anal 
cancer in the long-term. Therefore, it is important to compare patients who have had their 
HSIL actively monitored to those who have been treated in order to find the method that 
is both the most efficacious and least invasive in preventing anal cancer (Anal Cancer 
UCSF website, 2016).  
Motivations for Participating in Anal Cancer Prevention Research 
It is important to consider a person’s motivations for participating in an anal 
cancer prevention study. In order to improve retention rates in randomized control trials 
and remain ethical in randomizing patients, it is important to understand the patient 
experience before, in, and after participating in a study (Adams et al., 2015). There are a 
number of possible motivations for participants to volunteer in clinical research. Possible 
motivations include but are not limited to wanting to make a positive contribution to 
research and medicine, wanting to help other individuals who suffer from the same 
disease, monetary gain, following suggestions made by the patient’s clinician, gaining 
access to health care, and a hope for a cure or positive health outcome for the participant 
(Dainesi and Goldbaum, 2014). One study cited a common reason for individuals to 
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participate in an anal cancer screening study included having previous experience with 
the HRA exam (Battaglia et al., 2015). Additionally, altruism is a frequently accounted 
motivation for participation in AIDS-related research studies (Battaglia et al., 2015). 
Additionally, participants in Newman’s 2008 study reported that receiving a 
recommendation from a clinician to undergo anal cancer screening is a useful stimulus 
for seeking screening. Since anal cancer screening protocols have not been standardized, 
such screening may often be offered as part of a clinical trial.  
Retention in Anal Cancer Prevention Studies 
Retention is an important topic in clinical studies as it is important for a certain 
number of participants to remain in the study in order for results to have sufficient power. 
In the Anal Cancer HSIL Outcomes Research (ANCHOR) Study AIDS Malignancy 
Consortium 01 (AMC), approximately 17,585 HIV positive patients who are older than 
35 need to be screened in order to reach a sample size of 5,085 people with HSIL 
(ANCHOR website, 2016). With a sample of this size, methods need to be in place to 
optimize retention and minimize attrition. Participants can choose to leave a study at any 
time and should not be coerced to stay for any reason. With this said, public health 
employees, clinical staff members, and retention specialists can conduct qualitative 
research to find out reasons why participants drop out of studies and can attempt to 
improve the experience for participants in a study (Adams et al., 2015).  
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The Informed Consent Process 
The informed consent process involves the event in which the research participant 
authorizes their consent to participate in a study after being informed about the processes 
and procedures that will occur in the study (Dranseika et al., 2016). It is often difficult to 
assess a participant’s level of comprehension during or after the informed consent 
process. It is important for the clinical staff to do their best to convey the information 
about the study at a level that the participant can understand, and to focus on information 
that is relevant to the patient (Dranseika et al., 2016). One of the most common obstacles 
that can occur during the informed consent process is encountering participants that are 
illiterate or functionally illiterate (The Association of American Medical Colleges, 2007). 
As evidenced by the National Adult Literacy Survey of 1992, approximately half of 
adults in the United States are functionally illiterate (The Association of American 
Medical Colleges, 2007). While a clinical staff member often verbally summarizes the 
contents of the consent document to the participant before they sign, it is difficult to 
convey all the information of the often lengthy and dense documents. A study has yielded 
results of an inverse relationship between length of consent documents and patient 
comprehension (The Association of American Medical Colleges, 2007).  
Barriers to Participation in Anal Cancer Prevention Treatment and Research 
There are a number of possible deterrents for patients to participate in anal cancer 
screening. One major deterrent is the pain that occurs during the recovery from the HRA 
procedure (Battaglia et al., 2015). Pain and bleeding during bowel movements are not 
uncommon during recovery from the HRA procedure. Further research is needed to 
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identify pain during the HRA procedure as a deterrent. Additionally, a history of physical 
abuse and trauma, specifically in HIV positive women, was cited as a barrier to 
participation in anal cancer screening research (Battaglia et al., 2015). Another barrier to 
anal cancer screening is the lack of awareness of HPV and HPV related disease (Newman 
et al., 2008). Newman et al.’s 2008 study provided evidence that lack of awareness about 
HPV and its relation to cancer may be associated with racial or ethnic background, age, 
and sexual orientation. Another potential barrier is that it is not routine for clinicians to 
perform anal cancer screening. Patients may not feel like it is necessary to have anal 
cancer screening depending on their health care providers’ recommendations (Newman et 
al., 2008). Additionally, there is a shortage of clinicians who are trained in the HRA 
procedure (Palefsky, 2015). As suggested by Newman et al.’s 2008 study, a negative 
stigma of men receiving an anal pap test is also a potential barrier to receiving anal 
cancer screening. In a focus group, men stated that receiving anal cancer screening might 
stereotype them as being promiscuous and/or gay. Additionally, participants addressed 
additional concerns about the pap test include feeling emasculated, embarrassed, or 
experiencing psychological distress (Newman et al., 2008). A list of barriers to the DARE 
(digital anorectal exam) are listed in Table 2 (Ong et al., 2015).  
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Table 2. Major Themes of Barriers for Implementing DARE. Obtained from Ong et 
al., 2015. Barriers for implementing the digital anorectal exam (DARE) include system 
factors, health care provider factors, and patient factors.  
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METHODS 
Objectives 
The AIDS Malignancy Consortium’s (AMC) 076 protocol is a two-year 
randomized control trial (RCT) of infrared coagulation to treat HSIL compared with 
observation only. The goal of the present qualitative study (IMPACT 076) was to 
understand motivations for participation in AMC 076 in preparation for a larger, five-
year study of the efficacy of HSIL treatment in the prevention of anal cancer. The 
purpose of IMPACT 076 was to further understand patients’ motivations for participating 
in anal cancer prevention studies, with the goal of improving the experience for current 
and future participants in anal cancer prevention research. The focus of the present 
analysis was to understand the relationship with pain and/or experienced side effects in 
an anal cancer prevention study and a patient’s willingness to participate in a similar, 
five-year long anal cancer prevention study in the future. Qualitative methods are 
especially useful when little is known about the topic at hand and there is a need to 
identify specific patient concerns and barriers to participation including but not limited to 
emotional support, experience with discomfort or pain, stigma associated with HIV and 
HPV related disease, transportation issues, and other issues with the study. Obtaining 
qualitative data from interview recordings and transcripts can be an incredibly valuable 
tool for researchers and clinical staff members to improve some of these barriers to 
participation in anal cancer prevention studies and related research studies. In qualitative 
research, rather than collect survey responses for quantitative analysis, the unit of 
analysis is participant narratives about their experiences as a participant at particular 
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decision points when deciding whether to participate in the AMC 076 trial. Examples of 
these decision points can include how they first learned about the study, receiving their 
HSIL diagnosis, the clinical and randomization procedures, and communication with the 
study staff. Once the interview transcripts are available, the transcripts are read, 
segmented by topic, and coded to identify thematic patterns. In addition to thematic 
coding of the interview transcripts, Madeline MacDonald chose three participants to 
highlight as case studies. These participants were chosen due to the particularly rich and 
useful data provided in their interview. The purpose of these case studies was to analyze 
and learn from actual patient experiences in anal cancer prevention research in order to 
identify strategies for recruiting and retaining participants in the Anal Cancer HSIL 
Outcomes Research (ANCHOR) study, which involves similar populations and 
procedures to AMC 076, but over a longer time span. Additionally, Madeline MacDonald 
discussed her experience in conducting patient retention phone calls in the ANCHOR 
study in order to draw further conclusions about motivations for participation in anal 
cancer prevention research. She related what she has discovered in these phone calls to 
conclusions made from the analyzed transcripts from IMPACT 076.  
Study Participants 
All participants were recruited from the randomized control trial AIDS 
Malignancy Consortium (AMC) 076, an anal cancer prevention study. In order to be 
eligible to participate in AMC 076, a two-year long study, individuals met the following 
inclusion criteria: HIV positive diagnosis, male gender/sex, at least 35 years old, and 
diagnosis of HPV related HSIL upon anal cytology and anal biopsy results. Participants 
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who were eligible were then randomized to either the treatment arm or the observation 
arm of the study. In the treatment arm, study clinicians chose the appropriate course of 
treatment depending on the severity of the patients’ HSIL. Treatments included infrared 
coagulation, 5-FU topical cream, and ablative treatments including treatment under 
anesthesia. Participants in the observation arm were not initially treated but had High 
Resolution Anoscopies (HRAs) and DARE exams approximately every three months 
during the study. If a participant’s HSIL started to look suspicious of cancer, they were 
sent for treatment and their participation in the study ended. At the end of the first year of 
the study, participants in the observation arm were given the choice to be treated to have 
their HSIL removed. Approximately equal numbers of participants in the treatment and 
observation arms were recruited for the Investigating Motivations for Participating in 
Anal Cancer Trials (IMPACT) 076 study. To be eligible for the IMPACT 076 study, 
participants must have been able to speak English and were willing to participate in two 
phone interviews.  
Data Collection 
21 participants from three study sites were interviewed via telephone on two 
occasions by Nicolas Sheon PhD and Donna Neumark R.N. PhD between September 
2012 and September 2013. Phone interviews were arranged at times that were mutually 
convenient for both the participant and the researcher. The first interview was conducted 
between three and six months after the patient’s start of participation in the anal cancer 
prevention study AMC 076 and the second interview was conducted twelve months after 
the start of their participation. Only the interview transcripts from the first interview were 
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analyzed for this project because there was little difference in the data collected at the 
second interview. Interview questions were designed by the study principal investigator 
and subsequently approved by the CHR, however, the list of questions was used as a 
guide, rather than a script for the interview. The interview guide is included in Figure 1. 
Some additional questions were asked in some interviews and some questions were left 
out in other interviews, depending on the natural progression of the interview. Qualitative 
interview guides are more flexible than standardized surveys, as some questions can be 
deemed irrelevant based on a participant’s response to a previous question. Interviews 
took between 15 minutes and 77 minutes, with an average duration of 34 minutes. All 
interviews were recorded and transcribed for analysis.  
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Figure 1. Baseline Interview Conducted After Visit 3. This CHR approved list of 
questions includes a rough outline for the interview in the IMPACT 076 study.  
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Recruitment/Compensation 
Participants in the IMPACT 076 study were recruited from three AMC 076 study 
sites: The Anal Neoplasia Clinic at UCSF, Laser Surgery Care in New York City, and 
Cornell Clinical Trials Unit in New York City. Patients were referred to the study by the 
local study coordinator once they gave permission to be contacted for IMPACT 076. 
Patients who expressed interest were emailed the study information form and then 
verbally consented over the phone by the interviewer. Participants were paid $25 per 
interview, in the form of an Amazon E-gift card after completion of each interview. 
Patients were reminded of their interview date by email and were then called on their 
provided phone number for the interview.  
Potential Risks to Participants/Steps Taken to Minimalize Risk 
This was a low risk study, as there were no physical risks to participation. The 
primary risks involved discomfort, anxiety, or psychological distress when discussing 
HSIL diagnosis and treatment and their experiences of being diagnosed with HIV. The 
interviewers asked questions with a sensitive and compassionate demeanor to minimize 
the risks described above. The interviewers were both PhD level researchers who had 
extensive experience in interviewing patients. Dr. Neumark also worked as a study nurse 
at the UCSF study site and this experience provided necessary context for understanding 
the administrative and clinical aspects of HSIL diagnosis, study procedures and side 
effects. To minimize the loss of confidentiality, participants were assigned identification 
numbers that were associated with their audio recordings and transcripts, instead of their 
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names. The Human Subjects Committee of the University of California, San Francisco 
reviewed and approved all study procedures. 
Data Analysis 
Data collected in this study was qualitative and statistical analysis was not 
conducted. Audio recordings and interview transcripts were read and relevant segments 
from the interviews were coded and analyzed by Madeline MacDonald using an Excel 
matrix. Each row of the matrix represented one interview while thematic codes were 
arranged in columns. Relevant segments were entered into the appropriate cell at the 
intersection of each interview row and thematic column. Parent codes were assigned to 
major themes such as “altruism.” Sub-codes were then assigned to further categorize each 
theme. An example of a sub-code for altruism was “contributing to research/medicine.” 
Certain codes included all participants, however, some codes only pertained to certain 
participants. For example, the “pain associated with treatment” code pertained only to 
participants in the treatment arm or participants who had been previously treated before 
entering the study. Table 4 includes data from one of the codes that was analyzed in this 
project. While statistics were not performed, counts and totals were utilized to represent 
trends in the data in an organized fashion. For the case study portion of the project, 
Madeline MacDonald extracted direct quotes from the three chosen case study 
participants’ interview transcripts to display portions of the dialogue that highlight the 
study objectives and research question.  
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RESULTS AND DISCUSSION 
Participants were asked a question about whether or not they would consider 
participating in a five-year long randomized control trial (ANCHOR) that would have 
similar procedures to AMC 076. As in AMC 076, assignment to either the treatment or 
observation arm of the study would be random, but unlike the AMC 076, the trial would 
last five years. The research question about participation in the five-year study was 
hypothetical, as patients who had previously been treated for HSIL would not be eligible 
for ANCHOR. This question was asked to gain an understanding about motivations for 
participation in anal cancer prevention studies and not for the purpose of recruiting 
patients for ANCHOR. We categorized participants into one of four groups: treatment 
group/ treatment naïve, treatment group/ treatment experienced, observation group/ 
treatment naïve, and observation group/ treatment experienced. A treatment experienced 
participant had previously been treated for HSIL before entering AMC 076. A treatment 
naïve participant had not been previously treated for HSIL. Table 3 illustrates the number 
of participants that said they were willing to participate in the five-year study categorized 
by study group and previous treatment experience. When considering all participants who 
have received treatment at some point (either in the study or before the study), nine out of 
the thirteen would be willing to participate in the five-year study, three would not, and 
one was undecided. Battaglia et al.’s 2015 study on barriers and motivators of anal cancer 
screening concluded that individuals who have previous experience with the HRA 
procedure are more likely to be willing to participate in anal cancer screening research. 
Battaglia et al. also cited that participants are more likely to participate in anal cancer 
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screening research if they are not concerned about pain during the procedure (2015). 
Battaglia’s results, along with our results in Table 3 show that potential motivators for 
participation in anal cancer prevention research could involve prior experience with anal 
cancer prevention procedures/ treatments, usually with the same provider offering to 
enroll them in the AMC 076 trial. Previous HSIL treatment could thereby make it more 
likely for the participant to be willing to take part in the five-year trial. This makes sense 
since these participants had already developed a trusting relationship with the provider.  
However, participants who had been treated previously and had either had a negative 
experience with the procedures or were unwilling to be randomized would not have been 
willing to participate in the study. Such participants were not interviewed for the 
IMPACT 076 study. 
Of the 10 participants that reported about pain during the exam or treatment and 
were treated either before the study or during the study, three reported that the exam/ 
treatment was not painful. Two of the four patients reported that they would be willing to 
participate in the five-year study and one reported that he would not. Three patients 
reported some pain during their exam or procedure and of these three patients, all three 
reported that they would be willing to participate in the five-year study. Two patients 
reported severe pain during their treatment/exam. Of these patients, one patient was 
hesitant to participate in the five-year study and one patient would not participate in the 
five-year study. The participant was hesitant to participate due to the time commitment of 
the study and did not cite pain as a potential deterrent to participation. The patient that 
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would not participate in the five-year study also did not attribute pain to his deterrence 
for participation. When asked about his willingness to participate he stated, 
“No.. Too much, yeah. I think a year. This study is for a year isn't that bad 
not being treated. But I think five years would scare me even more than 
the year would have” (Phone Interview, November 8, 2012).  
He went on to describe his mother’s death from cancer and how he wanted to be 
aggressive in preventing cancer in himself. Therefore, he would not participate in the 
five-year study due to the chance of being randomized to the active monitoring arm of the 
study. Similarly, Landstra’s 2013 study cited that men who had a family member that had 
been diagnosed with prostate cancer were significantly more likely to want a more 
thorough prostate cancer screening test than those who did not have a family history of 
prostate cancer.  
Based on the participants’ reported pain during treatment, four out of the five that 
reported pain and were asked about participation in the five-year study were willing to 
participate in the five-year study. Battaglia et al. concluded that patients that experienced 
pain associated the anal pap test were not significantly less likely to participate in anal 
cancer prevention research (2015). Participant 076-222.1-130916 stated,  
“Yes.. So, [laugh] yeah, you know, and I was told I was very high 
tolerance of pain, so, um, this was, like, not a piece of cake, but, you 
know, it was up there. And, uh, like I said, if it - if it can - at first, when 
you're going through it, of course, you're - you're, like, "Why did I do this? 
I would never do this again…I would recommend it. I would tell someone, 
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you know, ‘Listen, if - if it's going to help you, do it’” (Phone Interview, 
September 16, 2013).  
Despite this participant’s experience with pain in the study, he was willing to participate 
in the five-year study because he valued the access to early detection of anal cancer.  
Side effects are common and to be expected after the anal exam/biopsies and 
treatments. Side effects can vary depending on treatment type, extent of disease, and due 
to other factors, such as previous trauma. Side effects include anal bleeding, perianal 
itching, anal pain, pain and bleeding associated with bowel movements, and more (Weis, 
2013). Side effects were classified as mild, moderate, or severe depending on the 
patient’s reported level of pain/discomfort, amount of bleeding reported, and duration of 
side effects. Table 4 summarizes the side effects that were extracted from the interview 
transcripts for each participant. Participant 076-208.1-130411 was classified as having 
severe side effects due to his description of his symptoms. He described his disruptive 
side effects when he stated,  
“It’s just this pressure on the prostate and this feeling, this urge to urinate 
and not being able to, it’s -- I don’t think there’s that much medication you 
can take for that” (Phone Interview, April 11, 2013).  
When asked about his willingness to participate in a five-year study, he said he 
would not participate.  
“You know, I -- it’s not a strong fear. I -- it’s like, it’s -- I fear pain more 
than I fear death” (Phone Interview, April 11, 2013. 
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 Therefore, his experienced side effects/pain were a barrier to participation in the five-
year study. Newman et al.’s 2008 study provided evidence that fear of physical and 
psychological discomfort are potential barriers to anal cancer screening. Participant 076-
222.1-130916, however, also experienced severe side effects but was willing to 
participate in the five-year study. 
“So even though - even though there's going to be discomfort for a while, 
it doesn't mean it's going to be all the time” (Phone Interview, September 
16, 2013).  
This patient had a history of severe pain due to a car accident. This suggests that having a 
history of other painful events might facilitate participation in anal cancer prevention 
procedures and treatments. Through analyzing segments of the transcripts related to side 
effects, it was concluded that participants who were treatment experienced or in the 
treatment arm of the study and experienced side effects were more likely than not to 
participate in the five-year study if they experienced mild to moderate side effects. Severe 
side effects, however, might be a more significant barrier to participation. 
When the interviewer asked the participants if they had ever considered dropping 
out of the study, ten out of the ten participants that were asked this question said that they 
did not wish to or did not plan on dropping out of the AMC 076 study. Two out of the ten 
participants reported that the time commitment or length of the commute would be the 
only reason to consider dropping out of the study. None of the participants reported pain 
or side effects as a potential reason to consider dropping out. Participants exhibited a 
strong level of commitment to the study. One possible limitation to these results could be 
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that the participants who agreed to participate in the IMPACT 076 study have a high 
level of commitment to the AMC 076 study, and are thereby more likely to have agreed 
to participate in the IMPACT 076 study. Aside from this limitation, a number of 
participants reported that they would not drop out of the study due to wanting to help 
others in some respect. This was coded as having altruistic motivations for participation. 
This topic will be discussed further within the conclusions about altruism. 
Participants reported on their health history and previous experiences dealing with 
pain, anal procedures, cancer, HIV diagnosis, and more. Four of the 21 interviewed 
participants previously had cancer of some sort and had undergone cancer treatment. One 
participant had participated in a number of clinical studies that involved painful 
procedures including a spinal tap. Five patients reported having anal warts removed in the 
past and two patients reported having experience with hemorrhoids being treated. One 
participant had previously suffered from a kidney stone. Five participants reported that 
they felt that they had a high pain tolerance. Four of these participants reported that the 
anal exam and treatment was not particularly painful for them. When grouping all 
participants that reported either previous invasive procedures or serious illness, five 
reported that they would be willing to participate in the five-year study, three said that 
they would not be willing to participate in the five year study, and one gave an 
inconclusive answer. The majority of participants who reported having serious health 
conditions such as cancer or who had invasive procedures such as surgical removal of 
anal hemorrhoids (excluding previous HSIL treatment) would be willing to participate in 
the five-year study. This observation could be related to the participant placing high value 
 28 
on medicine and medical procedures and altruistic motivations for participation. An 
example that led us to this conclusion is participant 076-223.1-130917’s discussion of his 
motivation for participation in clinical research.  
“I might as well see if we can help here, too. Uh, I tend to lean towards 
wanting to participate in these sorts of things just because I've known 
people that have, also, and - and, you know, well, I'm - I - I figure, I'm 
alive because of research, so, if - if I can participate in a little bit of that, 
then - that that's - you know, that's just karma” (Phone interview, 
September 17, 2013).  
This participant gives credit to clinical research for creating the HIV medications that he 
takes, which have likely extended his life. It is probable that he values participation in the 
anal cancer prevention study and would be willing to participate in future anal cancer 
prevention studies for similar reasons. Participant 076-222.1-130916 was in an accident 
and reported,  
“well, in, uh - four years ago, I was in a car accident and my face had to 
be, actually cut open, pull the whole skin down, and my face had to be 
reconstructed” (Telephone interview, Sept. 16, 2013).  
This participant describes his willingness to participate in the five-year study by relating 
it to pain he had experienced in the past.
“Yeah, so a lot of things have happened in my life. And this was, like, it 
was mild, and I say, you know, I could have just thought it was a broken 
nose and let it go. God knows where I'd be now if I didn't really, uh, you 
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know, push it and find out what's going on and take care of myself. And 
it's the same thing with this. It's - you got to take care of yourself. So even 
though - even though there's going to be discomfort for a while, it doesn't 
mean it's going to be all the time”.  
This participant’s experience exemplifies that having a high pain tolerance or having 
experienced pain that was more severe than the pain experienced during HSIL treatment 
could be a potential facilitator to participating in the five-year study.  
Participants were asked if they had a preference for the treatment or observation 
arm before being randomized in AMC 076. The preference of participants for a given 
trial group is summarized in Table 5 based on each participant’s prior treatment 
experience. Participants reported a variety of reasons for hoping that they had been 
randomized to either group. The most common reason that participants reported for 
preferring the treatment group was that they wanted the pre-cancerous lesions removed 
from their body as soon as possible, and preferred a more aggressive approach to 
preventing cancer. Participants that did not have a preference for either group stated that 
they would have trusted the clinician with providing them with either treatment that 
would remove their lesions or they would have trusted the clinician to closely monitor 
their lesions. One participant stated that he had hoped he would be randomized to the 
monitoring group because he felt it was a lesser time commitment. Participant 076-217.1-
130812 stated that he hoped he would be randomized to the observation arm so that, 
"you're not taking medicine you don't need” (Phone interview, August 12, 2013). Three 
participants hoped that they would be in the monitoring group because they wanted to 
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avoid painful treatments. Of these three participants, two were treatment experienced and 
one was treatment naïve. Participant 076-210.1-130522 had severe side effects after his 
previous anal surgeries and stated, 
“I think I would have probably said, no, I’m not going to be treated. I 
would have waited until he told me that [if] we were going to do it. And 
then I would have said, well, okay, no, I don’t want to do that” (Phone 
interview, May 22, 2013).  
He would have dropped out of the study as soon as he discovered that he had been 
randomized to the treatment arm after his past experiences with treatment. While two 
thirds of participants had an initial preference for one of the two study groups, one third 
of the participants did not have a strong preference for either group. While some 
participants who had previously received treatment preferred to receive treatment again, 
others wished to be observed and vice versa. Participant 076-218.1-130821 had 
previously been treated and hoped that he would be randomized to the treatment arm of 
the study.  
“I felt like I won. I, I felt like I won the lottery, I must admit. "F***, yes, I 
got it." Not so much as medication, but, I mean, I, I would think that 
people who were used to, um, having sort of to navigate the waters have 
been there for a long time, would want to be more aggressively treated, or 
is that not the case?” (Phone Interview, August 21, 2013).  
This participant describes a strong preference for the treatment group because of his 
experience with HIV treatment. Participant 076-207.1-130227 had also been previously 
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treated but he would have participated in the study if he had been randomized to either 
arm. He, however, did have a preference for the observation arm so that he could avoid 
“painful procedures” (Phone Interview, February 27, 2013). Preference for either arm of 
the study can therefore differ based on an individual’s experiences with treatment, their 
expectations, and feelings toward the urgency of treatment.  
An important topic to consider when enrolling patients in clinical studies is a 
patient’s motivation for participating in a clinical trial. One broad category that was 
coded for when analyzing the interview transcripts was motivation. When participants 
described their motivations stemming from wanting to help other people, altruism was 
coded for as the parent theme. Of the interviewed participants, 11 of the 21 were 
categorized as having altruistic motivations. The remaining 11 patients either did not 
comment on their motivation or did not specifically describe altruistic intentions as their 
motivation for participating in the clinical study. The category of altruism was then 
further broken down into subcodes of advancement of research/ medicine and empathy. 
Participant 076-223.1-130917’s motivation for participating in the study was categorized 
as altruistic and subcategorized as research/medicine. This categorization was made as a 
result of this statement,  
“I might as well see if we can help here, too. Uh, I tend to lean towards 
wanting to participate in these sorts of things just because I've known 
people that have, also, and - and, you know, well, I'm - I - I figure, I'm 
alive because of research, so, if - if I can participate in a little bit of that, 
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then - that that's - you know, that's just karma” (Phone interview, 
September 17, 2013).  
Participant 076-222.1-130916’s motivation was also categorized as altruistic and 
subcategorized as “empathy.” The statement that led to these categorizations was,  
“So, um, at first, I was, like, what - you know, what am I going - why did I 
do this? And then I said, "You know what? If it's helping somebody out 
that is going to go through what I went through, at least they know, 'Okay, 
well, we've heard this before. Do this, do that.' You know, if - if it's 
helping someone else, it's all worth it” (Phone interview, September, 16, 
2013).  
Battaglia et al.’s 2015 study cites that participants are motivated to participate in AIDS-
related research due to altruism, at least in part. Two of the reported motivations for 
participating in the clinical study that fell outside of the altruism category included 
curiosity about participating in a clinical study and following a clinician’s suggestion to 
enter the study. Additionally, the two altruism sub categories can be broken down even 
further, and still be classified as altruistic. For example, the research/medicine group can 
be broken down further into helping clinicians with their research. Some of the 
participants were already patients of the clinicians who conducted the AMC 076 study. 
When asked if they would be interested in participation in this study, some participated to 
help their clinician with their study, as they were already being treated for HSIL and had 
a great deal of respect for their clinician. Participant 076-210.1-130522 exemplifies this 
sub category in his statement.  
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“I wanted to help him. That’s -- I mean, that’s the -- he is a terrific doctor, 
he is a terrific person, and whatever I can do that isn’t of great risk to me 
that they can help someone else, then I’m willing to be part of it. That’s 
the reason I said yes” (Phone interview, May 22, 2013). 
When considering all motivations for participation in clinical research, altruism was the 
most commonly coded theme for motivation. There are some limitations to this 
conclusion because of the nature of the interview. Because this was an interview and not 
a survey, participants might not be comfortable fully disclosing their motivations to the 
interviewer. If their motivation is partially based on gaining access to specialized health 
care or for the chance to have early detection of anal cancer, they might be less likely to 
report this and could exaggerate their altruistic intentions.  
When considering the IMPACT 076 participants as a whole, it appears that pain 
and side effects were not a major barrier to participate in the five-year study. Based on 
the results of this study, the most common motivators for participation appeared to be 
altruism and early detection of anal cancer or prevention of anal cancer. The most 
common deterrent for participating in the five-year study was participants feeling that 
five years is too long to have their HSIL left untreated if they were to be randomized to 
the observation arm of the five-year study. In general, participants were able to deal with 
the pain and side effects of the exams and/or treatments in exchange for feeling confident 
that their HSIL would be removed and their risk of developing anal cancer was greatly 
reduced. Another deterrent to participation in anal cancer prevention research that was 
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brought up in this study was having an incidence or history of sexual abuse. This is an 
important topic that needs to be researched further.  
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Table 3. The Number of Participants That Would Participate in the Five Year Study 
Categorized by Study Group and Previous Experience With Treatment. Participants 
are broken up into groups based on treatment group and treatment experience. 
Participants are then categorized based on their willingness to participate in a five-year 
study. 
 
Previous Treatment 
Experience/Study Group 
# of 
participants 
that would 
participate 
in 5 year 
study 
# of 
participants 
that would 
not 
participate 
in 5 year 
study 
# of participants that were 
unsure 
Treatment 
Experienced/Treatment 
Group 
3 0 1 
Treatment 
Naïve/Treatment Group 
4 3 0 
Treatment 
Experienced/Observation 
Group 
2 0 0 
Treatment Naïve/ 
Observation Group 
3 2 0 
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Table 4. Table of the Code: Side Effects. This table displays the code for side effects 
and a brief description of the patient’s described side effects from treatment or the HRA 
procedure/exam.  
 
Participant ID Study Group Side Effect Description Side Effect Classification 
076-201.1-120920 
 
treatment bleeding for a week moderate 
076-202.1-121011 
 
observation bleeding and oozing for two 
weeks 
moderate 
076-203.1-121004 
 
treatment heavy bleeding, minimal 
pain 
moderate 
076-204.1-121108 
 
treatment pain for 2-3 days mild 
076-205.1-121211 
 
observation pressure/discomfort mild 
076-206.1-130116 
 
observation X X 
076-207.1-130227 
 
observation X X 
076-208.1-130411 
 
treatment pain/bleeding for two 
weeks. pressure on prostate- 
urge to urinate which was 
very disruptive to daily life 
severe 
076-209.1-130411 
 
treatment light pain and light bleeding mild 
076-210.1-130522 
 
observation pain and bleeding for a 
month 
severe 
076-211.1-130611 
 
treatment very minimal bleeding mild 
076-212.1-130611 
 
treatment light bleeding, no pain mild 
076-213.1-130808 
 
observation X X 
076-214.1-130722  
 
treatment light bleeding with bowel 
movements, discomfort 
X 
076-217.1-130812 
 
observation X X 
076-218.1-130821 
 
treatment light bleeding mild 
076-219.1-130822  
 
observation X X 
076-220.1-130822 
 
treatment small amount of blood on 
toilet paper 
mild 
076-221.1-130828  
 
observation X X 
076-222.1-130916 
 
treatment extreme pain, heavy 
bleeding, temporary fecal 
incontinence 
severe 
076-223.1-130917 
 
observation slight discomfort mild 
 
 
*X= no data reported, exempt from analysis on the side effect theme 
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Table 5. The Preferences of Trial Group Categorized by Experience With 
Treatment. Participants were broken up into groups based on prior treatment experience 
and then categorized based on their preference of treatment, observation group, or either 
group. 
 
 # of participants 
who preferred 
treatment 
# of participants 
who preferred 
observation 
# of participants 
with no preference 
Treatment 
Experienced 
2 4 2 
Treatment Naive 4 4 5 
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Case Studies 
Three participants were chosen to highlight as case studies because they had 
particularly rich dialogue on the coded themes and topics that were focused on in this 
project. The first participant is participant 076-222.1-130916. He was in the treatment 
arm of the study and was treated at the New York site with infrared coagulation. He had 
significant side effects after treatment, which included severe bleeding, and temporary 
fecal incontinence that required him to wear diapers for three to four days after the 
procedure. His side effects were amongst the most severe side effects experienced by 
participants in IMPACT 076. This participant had experienced severe pain in the past 
after getting in a serious car accident that resulted in a facial injury that required 
reconstructive surgery. He also had previous treatment under anesthesia for HSIL before 
he entered the AMC 076 study.  
Despite this participant’s severe side effects, when asked if he had considered 
dropping out of the study, he expressed his altruistic motivations for participation in the 
study. “No, it was, like I said, if it's helping other people.” (Phone interview, September 
16, 2013). When asked about his willingness to participate in a five-year study, he said he 
would be willing to participate. He explains that he felt a sense of ease knowing that his 
lesions would be either monitored or treated, and would even recommend the study to 
others for this reason. This participant’s motivations for participation in the study and his 
willingness to participate in the future study are noteworthy. He exemplifies the mindset 
that is common in clinical trial participants in that they believe that the treatment that 
they are receiving will be successful. While the point of the study is to test the 
 39 
treatment’s efficacy in preventing anal cancer, this patient had confidence that the 
treatment he received was effective in doing so, and would therefore participate in the 
five-year study, despite severe and temporarily debilitating side effects. 
The second case study is participant 076-219.1-130822. He was in the observation 
arm of the study and was seen at the New York site. He had no previous experience with 
HSIL treatment. He was the victim of sexual abuse as a child so the HRA procedure/ anal 
exam caused him anxiety and was painful for him. The participant described his 
experience during the exam. “Um, like, he had trouble with everything, and he knew that 
I was in pain. And it isn't really painful. I was making it painful, because I'm clenching 
up” (Phone interview, August 22, 2013). He chose to take a sedative during the exam to 
help him relax, so that the exam would not be so uncomfortable. When asked if he would 
participate in the five-year study, he said he would not for two main reasons. Firstly, five 
years would be too long for him to deal with the emotional trauma that the exam caused 
him. Secondly, he was not comfortable with the idea of having his HSIL actively 
monitored for such a long period of time. He would prefer to have his lesions treated at 
the end of the AMC 076 study and would not be comfortable being randomized to the 
observation arm of the five-year study. This participant’s openness about his past brings 
up a very important topic in anal cancer prevention research. It is possible that a number 
of participants in AMC 076 study and other anal cancer prevention studies suffered from 
this type of trauma or related abuse in their lifetime. The anal exams and treatments are 
invasive procedures and participants that have a history of trauma could benefit from 
prophylactically taking sedatives before the exam and/or treatment. The topic of 
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sexual/physical abuse in anal cancer prevention studies or treatment brings up an ethical 
concern. Should a clinician or clinical staff member ask participants about a history of 
abuse or would an invasive question of this nature possibly resurface trauma and cause 
the patient additional anxiety? Additional research on physical and sexual abuse and the 
HRA procedure/ HSIL treatments would need to be done to make conclusions about this 
question. Battaglia et al.’s 2015 study reported that one of the most frequently reported 
barriers to the anal pap test is the fear of the exam resurfacing memories of a previous 
sexual assault.  
076-211.1-130611 is the third case study. This participant was randomized to the 
treatment arm of the study and was treated with infrared coagulation at UCSF. He 
reported that the procedure was not painful and he had minimal side effects afterwards. 
He had previous procedures to remove cancerous lesions from his face when he had skin 
cancer and did not experience a lot of pain from those procedures. He attributed this to 
having a high pain tolerance. After being treated and surviving skin cancer, he was glad 
that he was randomized to the treatment arm of the AMC 076 study. Similarly, his HIV 
doctor instilled a proactive approach to treatment in him and he quoted his physician in 
his interview. With regards to his HIV treatment, his physician stated, “We’ve got to be 
aggressive” (Phone interview, June, 11, 2013). For this reason, the participant explained 
that he would not be willing to participate in the five-year study because he wanted his 
HSIL removed and would not risk being randomized to the observation arm. He referred 
to his HSIL as an “illness” that he wanted treated (Phone interview, June 11, 2013). An 
interesting point to note is that both participant 076-222.1-130916 and participant 076-
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211.1-130611 share a similar confidence that the HSIL treatments will be effective in 
preventing anal cancer. One prominent difference in their recovery experience, however, 
was that the first participant experienced severe side effects and the second participant 
did not experience side effects. Additionally, despite their shared beliefs in the 
importance of treatment/ removal of HSIL, the participants differed on their willingness 
to participate in the five-year study. The first participant would be willing to participate, 
however, the other participant would not be willing to participate because of the chance 
of being randomized to the observation arm of the study. In conclusion, AMC 076 
participants’ willingness to participate in the five-year study is based on a number of 
factors including pain/side effects, beliefs about the efficacy and urgency of treatment, 
and more.  
Comparisons to Motivations for Participation in the ANCHOR Study 
 It is possible that motivations for participation in AMC 076 may differ from 
motivations for participation in other anal cancer prevention studies. The proposed five-
year study discussed in IMPACT 076 is ANCHOR, an anal cancer prevention study. 
Madeline MacDonald and clinical research coordinator Ryan Gonzales have conducted 
retention phone calls with the UCSF ANCHOR participants from August 2015 through 
March 2016. The phone calls are short interviews that ask participants a range of 
questions including their level of comfort in the arm of the study that they are in, ways in 
which their study visits can be made easier, and about any concerns that the patient has 
with the study. Patients are also asked if they have considered or are considering 
dropping out of the study. These phone interviews are conducted every six months, 
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throughout the duration of the five-year study. In our experiences conducting phone 
interviews and through interacting with ANCHOR participants in the Anal Neoplasia 
Clinic at UCSF, we discovered that there is a wide range of potential motivators for 
participation in ANCHOR. The ANCHOR sample is broader than the sample of 
participants that were interviewed in IMPACT 076 in terms of demographics. ANCHOR 
includes women, whereas AMC 076 did not. Additionally, ANCHOR patients are paid 
$100 cash for each study visit in which an anal exam and anal biopsies are performed. 
This occurs approximately every six months for participants. The AMC 076 participants 
were not paid for their participation in the study. Additionally, ANCHOR includes more 
poor individuals who live in marginal housing. Many of the participants in ANCHOR are 
medically illiterate and have not heard of HPV and its relation to anal cancer before being 
consented for ANCHOR. The Newman et al. 2008 study similarly provided evidence that 
lack of knowledge about HPV and its relation to anal cancer is a barrier to anal cancer 
screening. Most of the AMC 076 participants, however, were already being treated for 
HSIL or were seeking HSIL treatment and were therefore aware of HPV and its sequelae. 
In ANCHOR, however, participants need to be actively recruited, as it is a much larger 
study. Participants are recruited from HIV care centers, flyers in the community, by word 
of mouth, and more. From our experiences in the Anal Neoplasia Clinic at UCSF, we 
have seen that some participants come into the ANCHOR study for monetary gain. There 
was an experience when a participant arrived late for his visit, and was unable to be seen 
that day. He was a poor individual and said that he was very upset that he could not been 
seen because he would not be paid, and as a result he would not be able to buy his 
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groceries. This was a tender situation for the clinical staff, as they felt compassion for this 
man. This issue, however, can be an obstacle in clinical research and should be 
considered when recruiting and enrolling participants. Similarly, when participants are 
asked in their retention phone calls if they have any additional questions about the study, 
participants have asked if they will be paid for their next study visit. In some of these 
cases, it is clear that the participant’s primary concern is their compensation, and they 
appear to be completely unaware of study procedures. One participant was not sure if he 
was in the treatment arm or active monitoring arm of the study. Another participant was 
not aware that he was in the study anymore. Lack of awareness of study procedures can 
be a problem for retention. The retention calls are therefore an important tool to remind 
patients about the study and study procedures when necessary.  
 Similar to the participants in IMPACT 076, a number of ANCHOR participants 
have demonstrated altruistic motivations for participation during the retention phone 
calls. Additionally, ANCHOR participants have discussed that their motivation to join 
ANCHOR was to have the chance of early anal cancer detection. Participants often 
discuss a family member’s battle with cancer, and how they want to be proactive in 
preventing cancer in themselves.  
Limitations 
All participants in the IMPACT 076 study were men, however anal cancer affects 
women, and women are eligible to participate in the ANCHOR study. If a similar study 
were conducted in the future, it would be beneficial to include women in the study to get 
a more representative sample of anal cancer prevention study participants. It would be 
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beneficial to ask women to compare experiences receiving a pap smear or cervical 
treatments to their experiences in the anal cancer prevention study. Women may have a 
different perspective or understanding of the benefits of anal cancer screening based on 
their experiences with cervical screening and treatment. 
Data was coded and analyzed by one person in this study. If multiple individuals 
coded and analyzed interview transcripts, new findings and conclusions could be made 
and additional codes and quotes could be suggested.  
One issue that was noted when analyzing data was that not every question from 
the interview guide was asked to every participant. While this was an interview guide and 
not an exact script, it would have been beneficial to have all responses from all 
participants.  
Additionally, participants were not categorized based on which treatment type 
they received. This was not done because participants were often unsure about the exact 
type of treatment that they received and this information was not made available to the 
IMPACT 076 researchers. More information could be extracted form the data if the 
participants were categorized based on treatment type because different treatments cause 
varying degrees of pain/ side effects. In a quality of life assessment study, participants 
who had Imiquimod treatment of their HSIL reported pain more frequently than 
participants who were treated via electrocautery at week eight of treatment. At week 20 
of treatment, however, participants who were treated with electrocautery were more 
likely than patients who were treated with fluorouracil to experience pain. This trend was 
observed because pain increased in patients over time in the participants treated with 
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electrocautery, whereas pain decreased over time in patients who were treated with 
fluorouracil. Another trial evidenced that 30% of patients who were treated with 
Imiquimod had anal bleeding, 40% of patients treated with fluorouracil had anal 
bleeding, and 69% of those treated with electrocautery experienced anal bleeding 
(Siegenbeek van Heukelom et al., 2016). As evidenced by the above statistics, pain can 
vary greatly based on the treatment type.  
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